Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 19;113(6):896-911.e9.
doi: 10.1016/j.neuron.2025.01.005. Epub 2025 Jan 31.

Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain

Affiliations

Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain

Churmy Y Fan et al. Neuron. .

Abstract

Chronic pain is a leading cause of disability, affecting more women than men. Different immune cells contribute to this sexual divergence, but the mechanisms, especially in females, are not well defined. We show that pannexin-1 (Panx1) channels on microglia and T cells differentially cause mechanical allodynia, a debilitating symptom of neuropathic pain. In male rodents, Panx1 drives vascular endothelial growth factor-A (VEGF-A) release from microglia. Cell-specific knockdown of microglial Panx1 or pharmacological blockade of the VEGF receptor attenuated allodynia in nerve-injured males. In females, nerve injury increased spinal CD8+ T cells and leptin levels. Leptin release from female-derived CD8+ T cells was Panx1 dependent, and intrathecal leptin-neutralizing antibody injection sex-specifically reversed allodynia. Adoptive transfer of female-derived CD8+ T cells caused robust allodynia, which was prevented by a leptin-neutralizing antibody or leptin small interfering RNA (siRNA) knockdown. Panx1-targeted approaches may alleviate neuropathic pain in both sexes, while T cell- and leptin-directed treatments could have sex-dependent benefits for women.

Keywords: Neuropathic pain; Pannexin-1; T cells; VEGF; allodynia; leptin; microglia; nerve injury; sex differences; spinal cord.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests T.T. is cofounder and CEO of AphioTx Inc. G.W.Z. is cofounder and CSO of Zymedyne Therapeutics. T.T. has patents for the use of Panx1-targeting therapies for opioid withdrawal and addiction. G.W.Z. has patents targeting voltage-gated calcium channels for use in chronic pain. The patents do not pertain to, or have relevance for, the current reported findings. There is no direct bearing, and there is no commercial gain from the findings reported in the manuscript.

Similar articles

Cited by

LinkOut - more resources